

Semester VII

Course Code	Name of the course		No. of hours per week (L/P)	Credit points
BP701T	Biostatistics Research methodology (Theory)		3	3
BP702T	Cosmetics and Cosmeceuticals (Theory)		2	2
BP703T	AI in Clinical applications (Theory)		2	2
BP704T	Modern Analytical Techniques (Theory)		3	3
BP705T	Pharmacovigilance (Theory)		3	3
BP706T	Pharmacy Practice (Theory)		3	3
BP707T	Regulatory Affairs (Theory)		2	2
BP708T AEC	BP708T AEC1	Current Good Manufacturing Practices (cGMP)	1	1
	BP708T AEC2	Pharmaceutical Automation		
	BP708T AEC3	Modern Techniques in Cellular Biology		
	BP708T AEC4	Medical Devices		
	BP708T AEC5	Transformation of Food Waste into Medicinal Products		
	BP708T AEC6	Biosimilars, Vaccines & Macromolecules		
BP709P	Modern Analytical Techniques (Practical)		3	1
BP710RP	Research Project		-	6
Total			22	26

* One course shall be selected from the list

The syllabi for elective subjects are given in the *appendix*

Course Code	Course Title			Course Type
BP701T	Biostatistics and Research Methodology (Theory)			Core
Credit	Hours Per Week (L-T-P)			Max. Hours.
	L	T	P	
3	3	--	--	45
Maximum Marks	SE		ESE	
75	30		45	

COURSE OBJECTIVES

The objectives of this course are to:

1. Introduce the fundamental concepts of biostatistics including types of variables, data collection methods, sampling techniques, and descriptive statistical measures used in pharmaceutical and biomedical research.
2. Develop understanding of probability theory, probability distributions, and sampling distributions used in the analysis of biological and pharmaceutical data.
3. Explain the principles of correlation and regression analysis for studying relationships between variables and predicting outcomes in pharmaceutical and healthcare datasets.
4. Provide knowledge of inferential statistical methods including estimation, confidence intervals, hypothesis testing, parametric and non-parametric tests, and analysis of variance.
5. Familiarize students with research methodology, experimental design, and scientific reporting practices relevant to pharmaceutical research and data interpretation.

Course Outcomes (CO):

CO No.	Upon successful completion of this course, the students will be able to:
1	Explain the basic concepts of biostatistics including variables, sampling methods, descriptive statistics, and graphical representation of biomedical data.
2	Apply probability concepts and probability distributions (binomial, Poisson, normal, t, F, and chi-square distributions) in pharmaceutical and healthcare data analysis.
3	Analyze relationships between variables using correlation and regression techniques and interpret their applications in pharmaceutical research.
4	Perform inferential statistical analysis including estimation, confidence intervals, hypothesis testing, ANOVA, and non-parametric tests for research decision-making.
5	Design and evaluate research studies by selecting appropriate research designs, sampling techniques, and statistical methods, and demonstrate competence in scientific reporting and ethical research practices.

Detailed Syllabus:

Unit No.	Topics	No. of Lectures
I	<p>Basic concepts of biostatistics</p> <p>1. Definition, meaning and type of variables Data – Meaning and methods of data collection, data preprocessing and cleaning Population and sample, Importance of sampling, Sampling methods Probability and non-probability sampling</p> <ul style="list-style-type: none"> o Probability sampling - Random, systematic, stratified, cluster sampling o Non-probability sampling - Convenience sampling, purposive sampling, snowball sampling <p>Types of statistics - Descriptive statistics and inferential statistics Descriptive statistics – Meaning and types of descriptive statistics</p> <ul style="list-style-type: none"> • Frequency distribution, measures of central tendency • Measures of dispersion – Range, variance and standard deviation. <p>Concept of degrees of freedom, quartiles, skewness and kurtosis Diagrammatic representation of frequency distribution</p>	9 hours
II	<p>Probability and probability distributions</p> <p>1. Probability and probability distributions- Classical probability and statistical probability Probability of union, intersection and complement of events, conditional probability, marginal probability</p> <p>2. Probability distributions- Meaning of a probability distribution Discrete probability distribution- Meaning and examples of discrete probability distribution, meaning of PMF Continuous probability distribution – Meaning and examples of normally distributed data, meaning of PDF</p> <ul style="list-style-type: none"> • Normal distribution – Meaning and characteristics of a normal distribution, parameters of a normal distribution, equation for PDF of a normal distribution. Pharmaceutical examples of data which can be modelled with Poisson Normal distribution. • Standard normal distribution, Z transformation, reading the table of Z values <p>Problems based on standard normal distribution, binomial and Poisson distributions</p> <p>3. Sampling distributions – Meaning of sampling distributions</p> <ul style="list-style-type: none"> • t distribution – the t statistic, equation for calculating t statistic, meaning of t distribution, meaning of degrees of freedom and their relevance to t distribution, reading and interpreting table of t values, applications of t distribution • F distribution – the F statistic, equation for calculating F statistic, meaning of F distribution, reading and interpreting table of F values • Chi square distribution – the Chi square statistic, meaning of chi square distribution, reading and interpreting the table of chi square values, applications of chi square distribution. 	9 hours

III	<p>Correlation and regression analysis</p> <p>1. Correlation analysis – Introduction to the concept of correlation between two variables, positive and negative correlation, no correlation, examples of positive, negative and no correlation Measurement of correlation -</p> <ul style="list-style-type: none"> • Pearson’s Correlation Co-efficient – Definition and formula, assumptions, range of Pearson’s correlation co-efficient, interpretation of sign and magnitude • Spearman’s Rank Correlation Co- efficient – Concept and when to use, procedure for calculation Spearman’s Rank Correlation Co-efficient. <p>Real life applications in pharmaceutical and health sciences Problems on calculation of these two types of correlation co-efficient, use of scatter plot Multiple correlation – Concept and applications.</p> <p>2. Regression analysis – Concept of regression, dependent and independent variables in regression analysis, simple linear regression, simple linear regression equation (method of least squares), calculation of slope and intercept, co-efficient of determination, interpretation of output of regression analysis, applications of regression analysis. Relationship between regression co-efficient and correlation co-efficient Problems on simple linear regression analysis for predicting values of dependent variables (pharmaceutical examples) Multiple linear regression-Concept and applications, meaning of overfitting and underfitting.</p>	9 hours
IV	<p>Inferential statistics</p> <p>1. Statistical estimation – Point estimates and interval estimates of population parameters from sample statistics Concept of confidence intervals. Confidence intervals for means using t values. Problems on generating confidence intervals</p> <p>2. Hypothesis testing – Concept, steps involved, type I and type II error, sample size and power of the test, p values, applications of hypothesis testing Parametric tests - t- tests (single sample t test, two independent samples t test, paired t test) ANOVA (one way and two way). Assumptions, procedure and applications (case studies using t tests and ANOVA) Hypothesis testing in regression analysis and correlation Non-parametric tests - Mann Whitney U test, Wilcoxon Sign Rank test, Kruskal Wallis test, Friedman test, Chi square tests. Assumptions, procedure and applications (problems on non-parametric tests)</p>	12 hours
V	<p>Research methodology</p> <p>Research – Meaning, importance and types. Types of research designs Research methodology – Based on the research question, selection of research design, defining the population and sample, selecting the sample size and sampling method, method of data collection and data analysis.</p>	6 hours

<p>Decision tree approach for selection of statistical tests on the basis of research question and type of data</p> <p>Descriptive research design – Examples of application Observational research design – Examples of application Experimental research design – Examples of application</p> <p>Scientific report writing, plagiarism, referencing styles, selection of research journals, abstracting services and databases</p> <p>Screening and Optimization – Concept and experimental designs used for screening and optimization including Plackett Burman design, factorial designs, D optimal design, sequential simplex design, central composite design and response surface methodology, blocking and confounding in experimental designs.</p>	
<p style="text-align: center;">Recommended References (Preferably latest editions)</p> <ol style="list-style-type: none"> 1. Bolton, S. <i>Pharmaceutical Statistics: Practical and Clinical Applications</i>. Marcel Dekker. 2. Daniel, W. W. <i>Biostatistics: A Foundation for Analysis in the Health Sciences</i>. Wiley. 3. Montgomery, D. C. <i>Design and Analysis of Experiments</i>. Wiley. 	



Course Code	Course Title			Course Type
BP702T	Cosmetics and Cosmeceuticals (Theory)			Core
Credit	Hours Per Week (L-T-P)			Max. Hours.
	L	T	P	
2	2	--	--	30
Maximum Marks	SE		ESE	
50	20		30	

COURSE OBJECTIVES

The objectives of this course are to:

1. Recognize the fundamental concepts and classification of cosmetics and cosmeceutical formulations and their packaging and testing.
2. Develop knowledge of some common dermatological, hair, and oral care issues and their respective cosmetic products.
3. Develop an understanding of herbal cosmetics and their principles of formulation.
4. Learn regulatory guidelines, labeling protocols, and packaging regulations for cosmetics and cosmeceuticals.
5. Study the recent trends of research in artificial intelligence (AI) in customized skincare and cosmetic innovation.

Course Outcomes (CO):

CO No.	Upon successful completion of this course, the students will be able to:
1	Classify cosmetics and cosmeceuticals based on application and dosage forms, and outline the role of formulation excipients.
2	Describe the formulation, preparation, packaging, and evaluation of cosmetics for skin, hair, and oral care, including herbal products.
3	Demonstrate knowledge of formulation and quality assessment of commonly used cosmetic products such as shampoos, soaps, lotions, and decorative cosmetics.
4	Identify the functional roles of cosmetic ingredients in managing skin, hair, and oral conditions.
5	Explain the roles of regulatory bodies and labeling standards, and discuss the integration of AI in personalized cosmetic formulation and virtual applications.

Detailed Syllabus:

Unit No.	Topics	No. of Lectures
I	Cosmetics and cosmeceuticals, Classification of Cosmetics (Cosmetics and Cosmeceuticals for Skin Care, Hair Care, Oral Care, foot care, body cavities, Decorative Cosmetics, Cleansing cosmetics, Perfumes and Fragrances.) Types of various dosage forms for Cosmetics, Common excipients for cosmetic.	6 hours
II	Common skin problems (Dry Skin, Oily skin, Pimples and acne, Pigmentation, Prickly heat and Sun burn) and general composition, method for preparation, packing and evaluation of the skin Cosmetics and cosmeceuticals. Herbal cosmetics for skin. Types of soaps, syndet bars, general composition, method for preparation, packing and evaluation of soaps. Introduction to Perfumes and toiletries.	6 hours
III	Common Hair problems, Hair Cosmetics and cosmeceuticals: Types of shampoos, general composition, method for preparation, packing and evaluation of shampoos. Introduction to hair oils, hair serums, conditioners, hair colors, Depilatory and shaving products. Herbal hair care products.	6 hours
IV	Various problems of oral cavity, Oral Cosmetics, and cosmeceuticals: general composition, method for preparation, packing and evaluation of mouth wash and toothpaste. Herbal oral care cosmetics. Types of Cosmetics for nails, eyes, body odor, lip care and cleansing. Intimate hygiene products for males and females.	6 hours
V	Role of Regulatory authorities for Cosmetics and cosmeceuticals (CDSCO and FDA). Cosmetics regulations 2020 and role of BIS. Role of certifying bodies like ECCERT and COSMOS in herbal cosmetics. Labeling requirement of cosmetics and Packaging of cosmetics. Testing as per BIS specification and analytical methods (including sensory test, sensitivity test).	6 hours

Recommended References (Preferably latest editions)

1. Baki, G. and Alexander, K. S. *Introduction to Cosmetic Formulation and Technology*. Wiley.
2. Barel, A. O., Paye, M. and Maibach, H. I. *Handbook of Cosmetic Science and Technology*. CRC Press.
3. Benson, H. A. E. and Watkinson, A. C. *Cosmetic Formulation: Principles and Practice*. CRC Press.
4. Chisvert, A. and Salvador, A. *Cosmetic Formulation of Skin, Hair and Nails*. Wiley.
5. Dweck, A. C. and Santos, P. F. *Formulating Natural Cosmetics*. Allured Publishing.
6. Matsumoto, M. *Cosmetic Science and Technology*. Elsevier.
7. Rosen, M. R. *Harry's Cosmeticology*. Chemical Publishing.

Course Code	Course Title			Course Type
BP703T	AI in Clinical applications (Theory)			Core
Credit	Hours Per Week (L-T-P)			Max. Hours.
	L	T	P	
2	2	--	--	30
Maximum Marks	SE		ESE	
50	20		30	

COURSE OBJECTIVES:

The objectives of this course are to:

1. Introduce AI applications in pharmacology, pharmacokinetics, and drug safety.
2. Enable students to apply supervised ML models to clinical and pharmacovigilance datasets.
3. Develop interpretation skills for predictive modeling in healthcare.
4. Build understanding of real-world healthcare data analytics.
5. Promote responsible and ethical AI usage in patient care.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to:
1	Explain the applications of AI & ML in pharmacokinetics, pharmacodynamics, and clinical decision-making.
2	Apply regression and classification models to analyze clinical, pharmacokinetic, and pharmacovigilance datasets.
3	Interpret predictive model outputs for adverse drug reactions, therapeutic response, and clinical risk assessment.
4	Evaluate the performance of machine learning models using healthcare metrics such as accuracy, sensitivity, specificity, precision, recall, and RMSE.
5	Analyze real-world healthcare datasets and assess the ethical and practical implications of AI-based clinical decision support systems.

Unit No.	Topics	No. of Lectures
I	<p>AI in Pharmacokinetics & Dose Optimization</p> <ul style="list-style-type: none"> • Review of pharmacokinetic parameters (C_{max}, T_{max}, AUC, clearance) • Modeling concentration-time relationships: Linear regression in PK data modeling, multiple regression for dose adjustment based on patient variables (age, weight, renal function) • Interpretation of regression coefficients in clinical context • Error metrics (RMSE, R²) in PK modeling • Limitations of linear modeling in nonlinear pharmacokinetics 	6 Hours
II	<p>AI in Drug Safety & Pharmacovigilance</p> <ul style="list-style-type: none"> • Overview of pharmacovigilance systems • Structure and data formats from real systems (e.g. FAERS, EudraVigilance) • Conceptual overview of frequency analysis and signal detection • Logistic regression for ADR risk prediction • Confusion matrix and clinical performance metrics • Sensitivity, specificity, precision, recall • Bias and confounding in observational datasets 	6 Hours
III	<p>AI in Personalized Medicine & Risk Stratification</p> <ul style="list-style-type: none"> • Concept of precision medicine • Patient covariates and therapeutic response • Logistic regression for disease risk prediction • Classification of responders vs non-responders • Evaluation metrics in healthcare prediction • Ethical implications of predictive modeling 	6 Hours
IV	<p>AI in Clinical Decision Support & Real-World Data</p> <ul style="list-style-type: none"> • Structure of Electronic Health Records (EHR) • AI in Clinical Decision Support Systems (CDSS) • Regression models for outcome prediction • Classification models for risk scoring • Real-world data analytics 	6 hours

	<ul style="list-style-type: none"> • Limitations of AI in clinical environments • Accountability and interpretability 	
V	<p>Guided Supervised Learning Project – Pharmaceutical and Clinical Applications</p> <p>Students will undertake a guided supervised learning project (individually or in groups) applying regression or classification models to pharmaceutical or clinical datasets.</p> <p>The project should include the following steps:</p> <ul style="list-style-type: none"> • Identification and definition of a relevant pharmaceutical or clinical problem • Selection of an appropriate publicly available dataset • Identification of predictor variables and outcome variables • Data preprocessing and preparation for analysis • Application of suitable supervised learning methods (e.g., linear regression or logistic regression) • Evaluation of model performance using appropriate metrics • Interpretation of results in the context of pharmaceutical or clinical relevance • Discussion of limitations, potential biases, and ethical considerations • Presentation of findings to faculty mentors or peers. <p>Suggested project topics (not limited to): Dissolution rate prediction, tablet hardness prediction, stability degradation modelling, quality control batch failure prediction, assay variability modelling, impurity prediction, moisture impact on formulation stability, coating thickness prediction, solubility enhancement modelling, tablet defect classification, adverse drug reaction (ADR) prediction, therapeutic response prediction using patient datasets, hospital readmission risk prediction, dose requirement prediction using pharmacokinetic data, diabetes risk prediction from health markers, antibiotic treatment success prediction, ICU stay duration prediction, medication adherence analysis, and disease severity classification.</p>	6 Hours
<p>Recommended References (Preferably latest editions)</p> <ol style="list-style-type: none"> 1. Aggarwal, C. C. and Reddy, C. K. <i>Healthcare Data Analytics</i>. CRC Press. 2. Bonate, P. L. <i>Pharmacokinetic–Pharmacodynamic Modeling and Simulation</i>. Springer. 3. Campbell, M. J., Machin, D. and Walters, S. J. <i>Medical Statistics: A Textbook for the Health Sciences</i>. Wiley-Blackwell. 4. Schmidt, S. and Derendorf, H. <i>Applied Pharmacometrics</i>. Springer. 5. Steyerberg, E. W. <i>Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating</i>. Springer. 6. Strom, B. L., Kimmel, S. E. and Hennessy, S. <i>Pharmacoepidemiology</i>. Wiley-Blackwell. 		

Course Code	Course Title	Course Type		
BP704T	Modern Analytical Techniques (Theory)	Core		
Credit	Hours Per Week (L-T-P)			Max. Hours.
	L	T	P	
3	3	--	--	45
Maximum Marks	SE	ESE		
75	30	45		

COURSE OBJECTIVES:

The objectives of this course are to:

1. Introduce advanced instrumental techniques used in pharmaceutical analysis,.
2. Provide conceptual understanding of modern separation and hyphenated analytical techniques.
3. Familiarize students with principles and applications of green analytical chemistry and sustainable analytical method development.
4. Explain the fundamentals of bioanalytical methods and immunoassays.
5. Introduce microscopy-based analytical techniques and highlight their role in structural characterization and pharmaceutical research.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to:
1	Apply the principle of Mass and NMR spectra in the structural elucidation of organic compounds.
2	Determine the physical nature of the drugs and excipients using thermal studies, X ray crystallographic techniques and microscopy based analytical techniques.
3	Apply the basic knowledge on radio immune assays in carrying out the immunological studies.
4	Understand the theoretical and practical's aspects of the latest hyphenated Chromatographic techniques used for analysis of drugs.
5	Apply green analytical chemistry techniques for environmental sustainability.

Detailed Syllabus:

Unit No.	Topics	No. of Lectures
I	1. Nuclear Magnetic Resonance Spectroscopy: Principles of ^1H -NMR and ^{13}C -NMR, various solvents used, chemical shift, factors affecting chemical shift, coupling constant, spin-spin coupling, relaxation, instrumentation of FT-NMR and its applications. 2. Mass Spectrometry: Principles, fragmentation and its rules, ionization techniques –	10 hour

	Electron impact, chemical ionization, MALDI, FAB, API, analyzers – Time of flight and quadrupole, ion trap, detectors and applications.	
II	<p>1. X-Ray Diffraction Methods: Origin of X-Rays, basic aspects of crystals, X-Ray crystallography, rotating crystal technique, single crystal diffraction, powder diffraction, structural elucidation and applications.</p> <p>2. Thermal Analysis: Introduction, instrumentation, factors affecting measurements, applications of TGA, DSC (types) and DTA.</p>	08 hour
III	<p>1. UPLC and Nano LC: Principle, advantages over LC and applications.</p> <p>2. Principle and applications of hyphenated techniques: GC-MS, LC-MS/MS, ICP-MS.</p> <p>3. Supercritical chromatography and flash chromatography: principles and applications.</p>	10 hour
IV	<p>1. Green Analytical Chemistry: Types of green solvents, various computational tools used to assess the greenness and its applications in sample preparation and analytical method development.</p> <p>2. Bio-analytical Methods: Introduction to bioanalytical method development, extraction of drugs and metabolites from biological fluids – SPE, LLE, PPE, BCS classification, PK-PD interaction, microsomal assays, MTT assay, BA & BE study protocol, biosimilars.</p> <p>3. Radio Immune Assays and ELISA: Importance, various components, principle, different methods, limitations and applications of radio immunoassay and ELISA.</p>	12 hour
V	<p>1. Microscopy-Based Analytical Techniques: Principle, instrumentation, and applications of optical microscopy, scanning electron microscopy and transmission electron microscopy.</p>	5 hour
<p>Recommended References (Preferably latest editions)</p> <ol style="list-style-type: none"> 1. Brown, M. E. <i>Introduction to Thermal Analysis: Techniques and Applications</i>. Springer. 2. Cullity, B. D. and Stock, S. R. <i>Elements of X-Ray Diffraction</i>. Prentice Hall. 3. Dong, M. W. <i>Modern HPLC for Practicing Scientists</i>. Wiley. 4. Friebolin, H. <i>Basic One- and Two-Dimensional NMR Spectroscopy</i>. Wiley. 5. Niessen, W. M. A. <i>Liquid Chromatography–Mass Spectrometry</i>. CRC Press. 6. Poole, C. F. <i>The Essence of Chromatography</i>. Elsevier. 7. Silverstein, R. M., Webster, F. X., Kiemle, D. J. and Bryce, D. L. <i>Spectrometric Identification of Organic Compounds</i>. Wiley. 8. Skoog, D. A., Holler, F. J. and Crouch, S. R. <i>Principles of Instrumental Analysis</i>. Cengage Learning. 		

Course Code	Course Title			Course Type
BP705T	Pharmacovigilance (Theory)			Core
Credit	Hours Per Week (L-T-P)			Max. Hours.
	L	T	P	
3	3	--	--	45
Maximum Marks	SE			ESE
75	30			45

COURSE OBJECTIVES:

The objectives of this course are to:

1. Understand the principles, scope, and importance of pharmacovigilance in ensuring drug safety and patient care.
2. Familiarize students with the classification of adverse drug reactions and the methods used for their detection, assessment, monitoring, and prevention within healthcare systems.
3. Explain the concepts and significance of immunovigilance in monitoring and managing adverse events following immunization.
4. Learn national and international regulatory frameworks, guidelines, and reporting systems related to pharmacovigilance and immunovigilance.
5. Analyze pharmacovigilance data and apply risk management strategies to enhance medication and vaccine safety.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to:
1	Explain the core concepts, objectives, and significance of pharmacovigilance and immunovigilance.
2	Interpret and analyze national and global regulatory frameworks related to drug and vaccine safety.
3	Identify, document, and report ADRs and AEFIs using appropriate pharmacovigilance systems.
4	Evaluate pharmacovigilance data to detect trends, safety signals, and risk factors associated with medicinal products.
5	Propose and implement risk management strategies aimed at improving patient safety and public health outcomes.

Detailed Syllabus:

Unit No.	Topics	No. of Lectures
I	Fundamentals of Pharmacovigilance <ol style="list-style-type: none"> Concept, history, and importance of pharmacovigilance Basic drug classification systems (introductory overview only): ATC classification, ICD <ul style="list-style-type: none"> ATC system ICD Drug-related problems and medication safety Drug safety considerations in special populations: <ul style="list-style-type: none"> Paediatrics Geriatrics Pregnancy and lactation 	10 hour
II	Pharmacovigilance Systems and Regulatory Framework <ol style="list-style-type: none"> Objectives and functions of pharmacovigilance Methods of pharmacovigilance data collection: <ul style="list-style-type: none"> Spontaneous reporting Cohort and case-control studies Global pharmacovigilance systems: <ul style="list-style-type: none"> WHO International Drug Monitoring Programme Role of CIOMS and major regulatory agencies (e.g., USFDA, EMA) Pharmacovigilance Programme of India (PvPI) Establishment and role of ADR Monitoring Centres 	10 hour
III	Adverse Drug Reactions (ADRs) <ol style="list-style-type: none"> Classification and types of ADRs Mechanisms and risk factors for ADRs Methods of ADR monitoring, detection, and reporting Assessment of causality, severity, predictability, and preventability of ADRs Management of ADRs Online reporting mechanisms and databases (WHO-ART, Vigibase, Vigiflow, Oracle Argus, OpenVigil software). MEDRA 	8 hour
IV	Immunovigilance and Other Disciplines of Pharmacovigilance <ol style="list-style-type: none"> Definition, scope, and significance of immunovigilance, cosmetovigilance, nutraceutical-vigilance, materiovigilance, herbovigilance, ecopharmacovigilance, and hemovigilance Vaccination failure and vaccine pharmacovigilance (vaccinovigilance) Overview of adverse events following immunization (AEFIs) Immunization safety monitoring systems in India 	7 hour
V	Risk Communication, Evaluation, Management, and ICH Guidelines <ol style="list-style-type: none"> Risk evaluation and management strategies in pharmacovigilance 	10 hour

<p>and immunovigilance</p> <p>b) Communication in drug safety crisis management</p> <p>c) Communication with regulatory agencies, business partners, and healthcare facilities</p> <p>d) Analysis of real-world case studies and lessons learnt</p> <p>e) Emerging trends and challenges in pharmacovigilance and immunovigilance</p> <p>f) Overview of safety data generation</p> <p>g) Objectives of ICH guidelines</p> <p>h) Expedited and aggregate reporting</p> <p>i) Individual Case Safety Reports (ICSRs)</p> <p>j) Periodic Safety Update Reports (PSURs)</p> <p>k) Post-approval expedited reporting</p> <p>l) Good Clinical Practices (GCPs) regulation 2019</p> <p>m) Application of pharmacogenomics and pharmacometrics in pharmacovigilance.</p>	
<p style="text-align: center;">Recommended References (Preferably latest editions)</p> <ol style="list-style-type: none"> 1. Andrews, E. B. and Moore, N. <i>Mann's Pharmacovigilance</i>. Wiley Blackwell. 2. Cobert, B. <i>Cobert's Manual of Drug Safety and Pharmacovigilance</i>. World Scientific Publishing. 3. Jose, J., Cox, A. R. and Paudyal, V. <i>Principles and Practice of Pharmacovigilance and Drug Safety</i>. Springer. 4. Strom, B. L., Kimmel, S. E. and Hennessy, S. <i>Textbook of Pharmacoepidemiology</i>. Wiley. 5. Talbot, J. and Waller, P. <i>Stephens' Detection of New Adverse Drug Reactions</i>. Wiley. 6. Waller, P. and Harrison-Woolrych, M. <i>An Introduction to Pharmacovigilance</i>. Wiley Blackwell. 	

Course Code	Course Title			Course Type
BP706T	Pharmacy Practice (Theory)			Core
Credit	Hours Per Week (L-T-P)			Max. Hours.
	L	T	P	
3	3	--	--	45
Maximum Marks	SE		ESE	
75	30		45	

COURSE OBJECTIVES:

The objectives of this course are to:

1. Understand the evolution, scope, and various roles of pharmacists in healthcare delivery systems.
2. Describe the structure and functions of hospital and community pharmacy, including drug distribution systems and regulatory standards.
3. Demonstrate knowledge of clinical pharmacy services and their application in drug therapy monitoring and patient care.
4. Develop skills in patient counseling, medication adherence strategies, and basic health screening services.
5. Apply prescribing guidelines, essential drug concepts, and principles of rational drug use to ensure safe and effective pharmacotherapy.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to:
1	Describe the evolution, scope, and settings of pharmacy practice, including roles of pharmacists in various levels of healthcare.
2	Explain the organization and functions of hospital and community pharmacies, including drug distribution systems and regulatory standards.
3	Demonstrate clinical pharmacy services such as drug therapy monitoring, drug information, and handling medication-related problems.
4	Apply patient-oriented services like medication adherence strategies, patient counseling, and communication techniques.
5	Interpret and apply prescribing guidelines, essential drug concepts, and principles of rational drug use for optimal pharmacotherapy.

Detailed Syllabus:

Unit No.	Topics	No. of Lectures
I	<p>Introduction to Pharmacy Practice Definition, scope and evolution of:</p> <ul style="list-style-type: none"> • Hospital and clinical pharmacy • Pharmacist's role from dispenser to healthcare provider • WHO and FIP guidelines on pharmacy practice • Pharmacy practice regulations in India • Role of pharmacy in public health and policymaking • Promoting rational use of medicines • Concepts of Good Pharmacy Practice • Pharmacy practice settings: inpatient, outpatient • Concept of healthcare delivery system and interprofessional collaboration • Primary (PHC), Secondary (CHC), Tertiary (District Hospitals, Medical Colleges) – role of pharmacists at various levels of care. 	8 hour
II	<p>Hospital and Community Pharmacy Hospital and its Organization Classification of hospitals, organizational structure of a hospital, healthcare staff involved in hospital services and their functions Hospital Pharmacy and its Organization Definition, organization structure, location, layout, and staff requirements, responsibilities and functions of hospital pharmacists Pharmacy and Therapeutic Committee Organization, functions, and policies, drug inclusion into formulary, inpatient and outpatient prescriptions, automatic stop order, emergency drug list preparation Hospital Formulary Definition of hospital formulary, contents of hospital formulary, differentiation between hospital formulary and drug list, preparation and revision of hospital formulary Drug Distribution System in a Hospital Drug procurement and inventory control, dispensing of drugs to inpatients, types of drug distribution systems, charging policy and labeling, dispensing of drugs to ambulatory patients, dispensing of controlled drugs, outpatient medication dispensing, NABH standards for medication management in hospital settings Community Pharmacy Organization and structure of retail and wholesale drug stores, types and design of a drug store, legal requirements for establishment and maintenance of a drug store, dispensing of proprietary products, maintenance of records of retail and wholesale drug stores, prescription handling, labelling, and patient counselling, introduction, definition, sale, and OTC medication list, vaccination services</p>	10 hour

III	<p>Clinical Pharmacy Services</p> <ul style="list-style-type: none"> • Introduction to clinical pharmacy and its concept • Drug therapy monitoring <ul style="list-style-type: none"> ○ Medication chart review ○ Clinical review ○ Pharmacist intervention ○ Ward round participation ○ Medication history ○ Pharmaceutical care • Drug information services • Drug/Medication related problems • Drug and poison information services • Therapeutic drug monitoring (TDM) 	9 hour
IV	<p>Patient-Oriented Services</p> <p>Medication Adherence and Non-Adherence Definition Factors influencing non-adherence Pharmacist's role in medication adherence Monitoring of patient medication adherence Tools used to assess medication adherence Strategies to overcome non-adherence</p> <p>Patient Counselling Techniques and Communication Skills Definition of patient counselling Steps involved in patient counselling Communication skills – communication with prescribers and patients Types of educational materials used in patient counselling Barriers to effective counselling – types and strategies to overcome barriers</p> <p>Health Screening Services Definition and importance Methods for screening: Blood pressure, Blood sugar, Body Mass Index, Lung function test Role of pharmacist in health screening services Telemedicine</p>	9 hour
V	<p>Prescribing Guidelines, Essential Drug Concept and Rational Drug Therapy</p> <p>Prescribing Guidelines Pediatrics, geriatrics, pregnant and lactating women ISMP guidelines for high risk medicines</p> <p>Essential Drug Concept WHO definition Core principles and key features Procedure involved in adding a drug into the essential drug list</p> <p>Rational Use of Medications</p> <ul style="list-style-type: none"> • Antibiotics • Antibiotic stewardship program <ul style="list-style-type: none"> ○ Injections ○ OTC drugs ○ Consequences of irrational drug use. • Dose calculations in chemotherapy, renal and hepatic failure 	9 hour

	patients.	
--	-----------	--

Recommended References (Preferably latest editions)

1. Hassan, W. E. Hospital Pharmacy. Lea & Febiger.
2. Harman, R. J. Handbook of Pharmacy – Health Care. Pharmaceutical Press.
3. Merchant, S. H. and Qadry, J. S. A Textbook of Hospital Pharmacy. CBS Publishers & Distributors.
4. Parmar, N. S. Health Education and Community Pharmacy. CBS Publishers & Distributors.
5. Parthasarathi, G., Hansen, K. N. and Nahata, M. C. A Textbook of Clinical Pharmacy Practice. Universities Press.
6. Shargel, L. Comprehensive Pharmacy Review. Lippincott Williams & Wilkins.



Course Code	Course Title			Course Type
BP707T	Regulatory Affairs (Theory)			Core
Credit	Hours Per Week (L-T-P)			Max. Hours.
	L	T	P	
2	2	--	--	30
Maximum Marks	SE		ESE	
50	20		30	

COURSE OBJECTIVES:

The objectives of this course are to:

1. Understand the drug discovery and development process.
2. Identify key regulatory authorities and their roles in drug regulation.
3. Describe the regulatory approval processes in India and international markets.
4. Understand the documentation and registration procedures for drug products.
5. Describe the laws and guidelines governing the pharmaceutical industry.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to:
1	Describe the fundamental concepts and organizational structures of regulatory affairs and global regulatory authorities governing pharmaceutical products.
2	Describe the drug discovery and development process, including preclinical, clinical, and regulatory documentation requirements.
3	Summarize the regulatory framework, approval procedures, and legal requirements for pharmaceuticals in India.
4	Compare regulatory approval processes and submission formats across major international markets.
5	Understand clinical trial requirements, ethics committee roles, informed consent, GCP guidelines, and pharmacovigilance requirements.

Detailed Syllabus:


Unit No.	Topics	No. of Lectures
I	<p>Fundamentals of Regulatory Affairs Introduction to Drug Regulatory Affairs, Overview of regulatory authorities in India and major international markets (US FDA, EMA, PMDA), Role and responsibilities of Regulatory Affairs Professionals, Organizational structure of regulatory bodies.</p> <ul style="list-style-type: none"> • Basic regulatory terminologies: Guidance, Guidelines, Regulations, Laws, Acts. • Regulatory reference resources: Orange Book, Purple Book, Federal Register, Code of Federal Regulations (CFR). 	6 hour
II	<p>Regulatory Requirements in Drug Development</p> <ul style="list-style-type: none"> • Drug discovery and development process, Drug development teams and their functions. • Non-clinical drug development: Pharmacology, Drug metabolism, Toxicology. • Regulatory documentation: Investigational New Drug (IND) application, Investigator's Brochure (IB), Clinical research protocols, Biostatistics in pharmaceutical product development, Bioequivalence (BE) studies, Data presentation for regulatory submissions. 	6 hour
III	<p>Indian Regulatory Framework and Approval Process</p> <ul style="list-style-type: none"> • Central Drugs Standard Control Organization (CDSCO) and State Licensing Authorities: Organization and responsibilities, Regulatory requirements for import, manufacture, and sale of pharmaceuticals in India, Certificate of Pharmaceutical Product (COPP), Regulatory approval procedure for new drugs in India, Clinical trial regulatory requirements in India, phytopharmaceutical regulations, Good Clinical Practice (GCP) guidelines and Schedule Y, Innovator and generic drugs, Generic drug product development • Phytopharmaceutical regulation by AYUSH and CDSCO. 	6 hour
IV	<p>International Regulatory Systems & Global Drug Registration:</p> <ul style="list-style-type: none"> • Types of regulatory applications: Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA) • Drug Master Files (DMF), Common Technical Document (CTD), electronic CTD (eCTD), ASEAN CTD (ACTD), • Registration procedure for Indian drug products in overseas markets, Post-approval changes to NDA and ANDA. 	6 hour

V	<p>Clinical Trials, Ethics, and Post-Marketing Surveillance:</p> <ul style="list-style-type: none"> • Clinical research phases (I-IV), Clinical trial documents, Institutional Review Board (IRB) and Independent Ethics Committee (IEC): Formation and functions • Informed consent process and documentation, Good Clinical Practice (GCP) obligations of investigators, sponsors, and monitors, Management and monitoring of clinical trials, Pharmacovigilance: Safety monitoring during clinical trials and post- marketing, 	6 hour
<p align="center">Recommended References (Preferably latest editions)</p> <ol style="list-style-type: none"> 1. Berry, I. R. and Martin, R. P. <i>The Pharmaceutical Regulatory Process</i>. Informa Healthcare. 2. Gallin, J. I. and Ognibene, F. P. <i>Principles and Practice of Clinical Research</i>. Academic Press. 3. Guarino, R. A. <i>New Drug Approval Process: Accelerating Global Registrations</i>. CRC Press. 4. Ng, R. <i>Drugs: From Discovery to Approval</i>. Wiley. 5. Pisano, D. J. and Mantus, D. S. <i>Textbook of FDA Regulatory Affairs</i>. Informa Healthcare. 6. Weinberg, S. <i>Guidebook for Drug Regulatory Submissions</i>. Wiley. 		



Course Code*	Course Title*	Course Type		
BP708T AEC1	Current Good Manufacturing Practices (cGMP)	Elective		
BP708T AEC2	Pharmaceutical Automation			
BP708T AEC3	Modern Techniques in Cellular Biology			
BP708T AEC4	Medical Devices			
BP708T AEC5	Transformation of Food Waste into Medicinal Products			
BP708T AEC6	Biosimilars, Vaccines & Macromolecules			
BP708T AEC7	Precision Medicine			
Credit	Hours Per Week (L-T-P)			Max. Hours.
	L	T	P	
1	1	--	--	15
Maximum Marks	SE		ESE	
50	20		30	

* One course shall be selected from the list
The syllabi for elective subjects are given in the *appendix*



Course Code	Course Title	Course Type		
BP709P	Modern Analytical Techniques (Practical)	Core		
Credit	Hours Per Week (L-T-P)			Max. Hours.
	L	T	P	
1	--	--	3	45
Maximum Marks	SE	ESE		
50	20	30		

COURSE OBJECTIVES:

The objectives of this course are to:

1. Provide practical training in interpretation of advanced instrumental data used for structural and physicochemical characterization.
2. Introduce quantitative analytical techniques using modern separation methods, such as UHPLC and HPLC, for the estimation of pharmaceutical substances.
3. Familiarize students with the principles and practice of green analytical chemistry, including preparation of green solvents and development of environmentally sustainable analytical methods.
4. Develop understanding of bioanalytical sample preparation techniques for pharmaceutical analysis in biological matrices, including solid phase extraction, liquid-liquid extraction, and protein precipitation.
5. Learn applied pharmaceutical analysis and methods including cell viability assays, residual solvent analysis, and estimation of drugs from biological fluids.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to:
1	Analyze and interpret proton NMR, carbon NMR, mass spectra, X-Ray diffraction patterns, and DSC thermograms to characterize pharmaceutical compounds.
2	Perform quantitative analysis of official pharmaceutical compounds using UHPLC.
3	Design and assess the suitability of green analytical solvents for pharmaceutical applications, promoting sustainability.
4	Construct a comprehensive protocol for bioavailability and bioequivalence studies adhering to USFDA regulatory standards.
5	Employ appropriate extraction techniques (SPE, PPE, LLE) for the accurate quantification of pharmaceuticals in biological fluids and matrices and explain and execute the MTT assay for evaluating cell viability in a laboratory setting.

Detailed Sllabus:**List of Practicals (Minimum 12 experiments must be performed)**

1. Interpretation of Proton NMR spectra of known compound (any two)
2. Interpretation of Carbon NMR spectra of known compound (any two)
3. Interpretation of mass spectrum of known compound (any two)
4. Interpretation of X-Ray diffraction spectrum (any one)
5. Interpretation of DSC Thermogram (any one)
6. Preparation and Evaluation of Green Analytical Solvents
7. Analytical method development by using Green chemistry
8. Quantification of pharmaceuticals in biological fluids using Solid Phase Extraction (SPE)
9. Quantification of pharmaceuticals in biological matrix by PPE
10. Quantification of pharmaceuticals in biological matrix by LLE
11. Demonstration of Cell Viability evaluation using MTT Assay
12. Demonstration on residual solvent analysis using GC
13. Assay of drug using HPLC (any two)
14. Analysis of drug from biological fluid using HPLC/ UV spectroscopy.

Recommended References (Preferably latest editions)

1. Beckett, A. H. and Stenlake, J. B. *Practical Pharmaceutical Chemistry*. CBS Publishers & Distributors.
2. Brittain, H. G. *Analytical Profiles of Drug Substances and Excipients*. Elsevier.
3. Kemp, W. *Organic Spectroscopy*. Palgrave Macmillan.
4. Munson, J. W. *Pharmaceutical Analysis: Modern Methods*. Marcel Dekker.
5. Sethi, P. D. *Quantitative Analysis of Drugs in Pharmaceutical Formulations*. CBS Publishers & Distributors.
6. Sharma, B. K. *Instrumental Methods of Chemical Analysis*. Goel Publishing House.
7. Sharma, Y. R. *Organic Spectroscopy*. S. Chand.
8. Silverstein, R. M., Webster, F. X., Kiemle, D. J. and Bryce, D. L. *Spectrometric Identification of Organic Compounds*. Wiley.
9. Willard, H. H., Merritt, L. L., Dean, J. A. and Settle, F. A. *Instrumental Methods of Analysis*. Brooks/Cole.
10. *Indian Pharmacopoeia*. Indian Pharmacopoeia Commission.

Course Code	Course Title	Course Type		
BP710RP	Research Project	CORE		
Credit	Hours Per Week (L-T-P)*			Max. Hours.
	L	T	P	
6	--	--	--	--
Maximum Marks	SE	ESE		
150	0	150		

* Refer section 21 of regulation.



SEMESTER VII

Course Code	Course Title			Course Type
BP708T AEC1	cGMP (Theory)			Elective
Credit	Hours Per Week (L-T-P)			Max. Hours
	L	T	P	
1	1	--	--	15
Maximum Marks	SE			ESE
50	20			30

COURSE OBJECTIVES:

The objectives of this course are to:

1. Explain the structure, purpose, and implementation of Standard Operating Procedures (SOPs) in pharmaceutical operations.
2. Develop understanding of training and development systems, including training needs assessment and evaluation methods used in the pharmaceutical industry.
3. Describe the principles of current Good Manufacturing Practices (cGMP) and key regulatory guidelines relevant to pharmaceutical quality assurance.
4. Examine core pharmaceutical quality systems such as Quality Management Systems (QMS), CAPA, deviation management, and non-conformance handling.
5. Understand procedures for managing customer complaints, investigating quality issues, and ensuring product safety and regulatory compliance.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to
1	Understand the structure of SOPs, its writing and approval system, Importance of training, development, training needs identification and evaluation.
2	Understand the major FDA guidelines (regulated and semi regulated markets) and its understanding.
3	Impart knowledge on manufacturing assurance, analytical assurance, engineering assurance etc, and handling systems for non-conformances.
4	Procedures used to investigate market complaints and its closure.
5	Impart knowledge on preparing for the regulatory audits, reports handling and drafting of compliance report, with certain understanding of Do's and Don'ts during the audits.

Detailed Syllabus

Unit No.	Topics	No. of Lectures
I	Standard Operating Procedures (SOP), Systems for Training & Development in Pharmaceuticals <ul style="list-style-type: none"> • Introduction to SOPs, SOP on SOP, Contents of a standard SOP, Writing a good SOP, Distribution and control of SOPs. • Introduction to Training and development, Training needs identification, Training and evaluation. 	3 hours
II	A comprehensive review of cGMP and various important FDA guidelines <ul style="list-style-type: none"> • List of major guidelines referred in pharmaceuticals • Effectively reading and understanding the guidelines 	3 hours
III	Important Quality Assurance and cGMP systems adopted in Pharmaceuticals <ul style="list-style-type: none"> • Introduction to Quality Management Systems (QMS), Manufacturing Assurance, Analytical Assurance, Developments Quality Assurance, Engineering Assurance. • Concepts of corrective and preventive actions (CAPA), Deviations and Incidents handling. Handling of non-conforming materials	3 hours
IV	Handling of Customer Complaints <ul style="list-style-type: none"> • Introduction to complaints, Types of complaints • Understanding Manufacturing defects and Quality issues • Handling and investigation of customer complaints 	3 hours
V	Regulatory Audits <ul style="list-style-type: none"> • Introduction to audits and Types of audits. • Preparation for a successful audit, Audit teams and internal audits. • Handling of FDA inspections: FDA observations, Compliance and replying to an audit report. 	3 hours

Recommended References (Preferably latest edition):

1. Good Manufacturing Practices for Pharmaceuticals – Joseph D. Nally, CRC Press
2. Quality Assurance of Pharmaceuticals: A Compendium of Guidelines and Related Materials (Vol. 1 & 2) – World Health Organization (WHO), WHO Press
3. Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations – U.S. FDA, CDER/CDRH Guidance Document
4. Pharmaceutical Production and Packaging Technologies – Michael J. Groves, CRC Press
5. Pharmaceutical Quality by Design: A Practical Approach – Walkiria S. Schlindwein & Mark Gibson, Wiley
6. Government of India, Ministry of Health and Family Welfare (2023) Drugs and Cosmetics Rules, 1945: Amendment introducing revised Schedule M – Good Manufacturing Practices. Gazette of India, Notification G.S.R. 922(E), 28 December.

Course Code	Course Title			Course Type
BP708T AEC2	Pharmaceutical Automation (Theory)			Elective
Credit	Hours Per Week (L-T-P)			Max. Hours
	L	T	P	
1	1	--	--	15
Maximum Marks	SE			ESE
50	20			30

COURSE OBJECTIVES:

The objectives of this course are to:

1. Introduce the fundamental concepts of automation technologies used in the pharmaceutical industry.
2. Explain the application of automated systems in pharmaceutical manufacturing, quality control, and packaging operations.
3. Describe the principles of process instrumentation, SCADA, PLC, and robotics in pharmaceutical production environments.
4. Develop understanding of laboratory automation systems including LIMS and Process Analytical Technology (PAT).
5. Examine regulatory considerations and emerging trends in pharmaceutical automation and digital manufacturing.

COURSE OUTCOMES (CO):


CO No.	Upon successful completion of this course, the students will be able to:
1	Explain the principles and advantages of automation in pharmaceutical processes.
2	Identify and describe various automated systems used in production and quality control.
3	Apply knowledge of instrumentation and control systems like SCADA and PLC in pharma environments.
4	Analyze the role of automation in enhancing data integrity, regulatory compliance, and productivity.
5	Evaluate new trends like Industry 4.0, IoT, and AI applications in pharmaceutical automation.

Detailed Syllabus

Unit No.	Topics	No. of Lectures
I	Introduction to Automation in Pharmaceuticals <ul style="list-style-type: none"> • Definition and scope of automation in pharmaceutical industry • Importance and benefits: accuracy, efficiency, cost-effectiveness, compliance • Types of automation: fixed, programmable, flexible • Application areas: production, packaging, quality control, warehousing • Challenges and limitations of automation 	3 hours
II	Automated Manufacturing Systems <ul style="list-style-type: none"> • Principles of automated tablet compression, capsule filling, liquid filling, and coating machines • PLC-based machinery in granulation and drying • Robotics in sterile product manufacturing (isolators, RABS) • Continuous manufacturing vs. batch processing • Automation in aseptic processing and lyophilization 	3 hours
III	Process Control and Instrumentation <ul style="list-style-type: none"> • Sensors and transducers: temperature, pressure, flow, pH, conductivity • Introduction to SCADA (Supervisory Control and Data Acquisition) systems • Distributed Control Systems (DCS) in pharma • Process Analytical Technology (PAT) – definition and applications • Basics of automation programming (ladder diagrams, logic gates – overview only) 	3 hours
IV	Quality Control and Laboratory Automation <ul style="list-style-type: none"> • Automation in analytical laboratories: HPLC, UV, FTIR, dissolution testers • Laboratory Information Management System (LIMS) • Integration of instruments with software and data loggers • Automated sampling and testing methods • Role of AI/ML in predictive quality assurance 	3 hours
V	Regulatory Aspects and Emerging Trends <ul style="list-style-type: none"> • Regulatory expectations: USFDA, WHO, EMA on automation & electronic systems • 21 CFR Part 11 – electronic records and signatures • Data integrity and ALCOA • Emerging trends: IoT, Industry 4.0, cloud-based manufacturing, AI in pharma • Case studies: automated systems in top pharma companies 	3 hours

Recommended References (*Preferably latest edition*):

1. Automation and Control in the Pharmaceutical Industry by Burton H. Sage, CRC Press
2. Pharmaceutical Engineering by K. Sambamurthy, New Age International Publishers
3. Process Automation Handbook by Jonathan Love, Springer-Verlag London Ltd.
4. Industrial Automation and Robotics by Mikell P. Groover, Pearson Education
5. Instrumentation and Process Control by Terry L.M. Bartelt, Cengage Learning
6. Good Automated Manufacturing Practice (GAMP 5 Guide) by ISPE (International Society for Pharmaceutical Engineering), ISPE Publications
7. Pharmaceutical Manufacturing Handbook: Production and Processes by Shayne Cox Gad, Wiley-Interscience



Course Code	Course Title			Course Type
BP708T AEC3	Modern Techniques in Cellular Biology (Theory)			Elective
Credit	Hours Per Week (L-T-P)			Max. Hours
	L	T	P	
1	1	--	--	15
Maximum Marks	SE			ESE
50	20			30

COURSE OBJECTIVES:

The objectives of this course are to:

1. Learn the basics of five key cell-biology tools: CRISPR editing, flow cytometry, live-cell imaging, single-cell RNA-seq, and advanced fluorescence microscopy.
2. Plan good experiments by picking the right reagents, controls, and settings for each technique.
3. Get hands-on practice using at least one workflow from every unit.
4. Read and understand the data these methods produce—plots, images, and gene-expression maps.
5. Apply the methods responsibly by considering safety, ethics, and real-world biomedical uses.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to
1	Explain key principles of CRISPR editing, flow cytometry/FACS, live-cell imaging, single-cell RNA-seq, and advanced fluorescence microscopy.
2	Design and carry out one basic protocol for each technique (e.g., gRNA design, four-colour FACS run, 12-h time-lapse capture, scRNA-seq data import, confocal Z-stack acquisition).
3	Interpret the resulting data by creating clear plots, images, or cluster maps and extracting at least one biological conclusion from each.
4	Choose the right technique for a given cellular-biology question and justify the choice with brief technical and practical reasoning.
5	Apply essential safety, ethical, and data-quality guidelines while performing and reporting every experiment

Detailed Syllabus

Unit No.	Topics	No. of Lectures
I	CRISPR & Genome Editing CRISPR-Cas9 mechanics, guide-RNA design and DNA repair outcomes, contrasts knock-outs, knock-ins and base-editing, and shows how dCas9 fusions enable gene activation or repression. Students compare delivery routes—plasmid, ribonucleoprotein, viral and lipid-nanoparticle—then	3

	evaluate off-target detection strategies before a mini-lab in which they design a gRNA and screen predicted off-targets.	
II	Flow Cytometry & Cell Sorting Learners review flow-cytometer fluidics, optics and fluorochrome chemistry, interpret forward/side scatter plots for cell size and granularity, and build multi-colour antibody panels with compensation. They perform cell-cycle, apoptosis and immunophenotyping assays, study FACS sorting logic and viability checks, and finish with a hands-on run of a four-colour immunophenotyping panel.	3
III	Live-Cell Imaging This unit covers phase-contrast, DIC and fluorescence time-lapse microscopy, stressing environmental control through on-stage incubators and microfluidic perfusion. Students deploy fluorescent reporters such as GFP fusions and calcium biosensors to track motility, division and signalling, learn to minimise phototoxicity and manage large image datasets, then conduct a 12-hour GFP-cell time-lapse demo.	3
IV	Single-Cell RNA-Seq & Multi-Omics Participants examine single-cell isolation by droplets, microwells or FACS, walk through barcoding, library preparation and sequencing, and run a basic bioinformatics pipeline for quality control, normalisation, clustering and UMAP/t-SNE visualisation. They identify cell types, trajectories and rare populations, glimpse CITE-seq and spatial transcriptomics, and explore a public scRNA-seq dataset in R/Python during a workshop.	3
V	Advanced Fluorescence & Super-Resolution Microscopy Confocal and two-photon fundamentals, followed by super-resolution strategies—STED, SIM and PALM/STORM—plus functional techniques such as FRET, FRAP and FLIM for probing protein interactions and dynamics. Learners plan multiplexed staining with spectral imaging, discuss clinical applications including FISH and diagnostic immunofluorescence, and acquire and process a confocal z-stack in a practical sessions.	3

Recommended References (Preferably latest edition):

1. Brown TA. Gene Cloning and DNA Analysis: An Introduction. 8th ed. Hoboken: Wiley-Blackwell; 2023.
2. Ormerod MG. Flow Cytometry: A Practical Approach. 4th ed. Oxford: Oxford University Press; 2014.
3. Goldman RD, Swedlow JR, editors. Live Cell Imaging: A Laboratory Manual. 2nd ed. Cold Spring Harbor: CSHL Press; 2010.
4. Tang F, Van Oudenaarden A, editors. Single-Cell RNA Sequencing: Methods and Protocols. 2nd ed. New York: Humana Press; 2021.

Course Code	Course Title			Course Type
BP708T AEC4	Medical Devices (Theory)			Elective
Credit	Hours Per Week (L-T-P)			Max. Hours
	L	T	P	
1	1	--	--	15
Maximum Marks	SE			ESE
50	20			30

COURSE OBJECTIVES:

The objectives of this course are to:

1. Understand the Evolution and Regulatory Landscape: Gain insights into the history, market trends, and regulatory frameworks governing medical devices in India and globally.
2. Master Design and Biocompatibility Principles: Learn the principles of medical device design, selection of materials, and the importance of biocompatibility in device development.
3. Implement Quality Systems in Manufacturing: Understand the application of Good Manufacturing Practices (GMP), quality assurance, and risk management in medical device production.
4. Navigate Regulatory Affairs for Global Market Access: Acquire knowledge of regulatory requirements and strategies for medical device approval and post-market surveillance in various regions.
5. Explore Emerging Technologies in Biomedical Engineering: Investigate the integration of electronics, sensors, and software in medical devices, and address ethical considerations in their development and use.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to
1	Analyze Market Trends and Regulatory Policies: Assess the evolution of the medical device industry and the impact of regulatory frameworks on market dynamics across regions.
2	Design Safe, Effective, and Compliant Medical Devices: Apply design principles, emerging technologies (sensors, electronics, software), and appropriate biomaterials to develop medical devices that ensure safety, efficacy, biocompatibility, and functionality.
3	Implement Quality and Risk Management Systems: Apply ISO 13485 standards, risk management processes, and ethical principles to ensure quality, safety, and responsible device development.
4	Navigate Global Regulatory Pathways: Understand and apply regulatory approval processes for medical devices in India, the US, the EU, and other regions.
5	Develop Post-Market Surveillance Strategies: Design and implement strategies to monitor performance, safety, and compliance of medical devices after market launch.

Detailed Syllabus

Unit No.	Topics	No. of Lectures
I	Introduction to Medical Devices: History and Overview of Medical Device Industry and evolving market Trends 1. (India + WW) 2. GOI's initiatives and National Medical Device Policy. 3. Regulatory frameworks (CDSCO; State FDA; USFDA; EU-CE, etc.) 4. Medical device design and development process 5. Definition and Classification of Medical Devices (India; US; EU)	3 hours
II	Medical Device Design, Biomaterials and Biocompatibility: 1. Medical Device Design principles and methodologies, safety analysis 2. Properties and selection of materials & biomaterials for devices 3. Tissue engineering and regenerative medicine 4. Biocompatibility Testing and Standards (ISO 10993)	3 hours
III	Manufacturing and Quality Systems: (based on ISO 13485 Fifth Sch of IMDR 2017) 1. Good Manufacturing Practices (GMP) & Infrastructure requirements 2. Quality assurance and quality control in Medical Devices 3. Supply chain management (warehousing distribution) 4. Risk Management (ISO 14971)	3 hours
IV	Regulatory Affairs, Regulatory strategies for global market access 1. Medical device regulations and standards (IMDR 2017) 2. Understanding Regional Differences in Regulatory Pathways 3. Regulatory submissions and approvals (India) 4. Post-market surveillance and vigilance (India) 5. Global Regulatory Requirements (USFDA, CE Mark, etc.) 6. Case Studies of Global Regulatory Challenges	3 hours
V	Biomedical Engineering; Instrumentation: Emerging Technologies 1. Principles of biomedical sensors and transducers 2. Medical imaging techniques (X-ray, CT, MRI, ultrasound) 3. Telemedicine and remote monitoring 4. Integration of Electronics and Software in Medical Devices 5. Wearable Devices and Remote Monitoring 6. Ethical issues in device development and use	3 hours
Recommended References (Preferably latest edition): 1. Ramakrishna, S., Mayer, J., Wintermantel, E., Leong, K. W. Biomedical Materials and Devices. Springer, Singapore. 2. Enderle, J. D., Bronzino, J. D., Blanchard, S. M. Introduction to Biomedical Engineering. Academic Press (Elsevier).		

3. Bronzino, J. D., Peterson, D. R. (Eds.) The Biomedical Engineering Handbook. CRC Press, Taylor & Francis.
4. Ratner, B. D., Hoffman, A. S., Schoen, F. J., Lemons, J. E. Biomaterials Science: An Introduction to Materials in Medicine. Academic Press (Elsevier).
5. Walsh, S. T. Medical Device Technologies: A Systems Based Overview Using Engineering Standards. Academic Press (Elsevier).
6. FDA / CDSCO. Medical Device Regulations and Regulatory Affairs. Government Publications (USFDA / Government of India).
7. Sharma, S. K. Medical Device Design and Development. McGraw-Hill Education.
8. Bhat, S., Kotian, S. Biomedical Instrumentation. PHI Learning Pvt. Ltd.
9. Webster, J. G. (Ed.) Medical Instrumentation: Application and Design. Wiley India.
10. ISO / BIS. Quality Management Systems for Medical Devices (ISO 13485 & ISO 14971). International Organization for Standardization.
11. Fitzpatrick, R., et al. Ethics and Regulation of Medical Devices. Oxford University Press.
12. Panchal, H., Patel, D. Regulatory Affairs for Medical Devices. PharmaMed Press.

Course Code	Course Title			Course Type
BP708T AEC5	Transformation of Food Waste into Medicinal Products (Theory)			Elective
Credit	Hours Per Week (L-T-P)			Max. Hours
	L	T	P	
1	1	--	--	15
Maximum Marks	SE			ESE
50	20			30

COURSE OBJECTIVES:

The objectives of this course are to:

1. Explain the sources, environmental impacts, and regulatory aspects of food waste.
2. Describe sustainable principles and technologies used in food waste management.
3. Explore methods for converting food waste into value-added products.
4. Discuss the recovery of bioactive compounds from food waste and their potential applications.
5. Introduce the use of artificial intelligence and digital technologies in food waste management and resource optimization.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to
1	Identify types, sources, impacts, and regulations related to food waste.
2	Apply principles and sustainable technologies for effective food waste management.
3	Explain the conversion of food waste into biofuels, biopolymers, and other value-added products.
4	Assess bioactive compounds derived from food waste and their industrial and health applications.
5	Understand the role of AI, IoT, and blockchain in smart food waste management systems.

Detailed Syllabus

Unit No.	Topics	No. of Lectures
I	Introduction to Food Waste Food waste: Definition, Types, Sources, Causes, Problems, Impacts Advantages, Challenges, Solutions and Future directions Indian and International regulations for food waste management	3 hours
II	Sustainable Management of Food Waste Principles of Food waste Management Technologies and Processes: Thermo-chemical Processes, Biological Processes, Green extraction, Pyrolytic and Enzymatic techniques	4 hours
III	Byproducts from Food Waste Production of Biohydrogen, Biogas, Organic acids, Vermicompost, and Biopolymers	3 hours
IV	Bioactive Compounds from Food Waste Antimicrobial, Antioxidants, Anti-inflammatory agents, Antibiotics, Prebiotics, Nutritional Supplements, Cosmetics and Biopolymers 3D printed medicines: Customized dosages and Scaffolds	3 hours
V	Role of AI in Food waste management Machine learning, IoT and Blockchain	2 hours
Recommended References (Preferably latest edition): <ol style="list-style-type: none"> 1.Ranjna Sirohi et al., 2025. Sustainable Technologies for Food Waste Management. Taylor and Francis Group. 2.Monika Thakur et al., 2020. Sustainable Food Waste Mangement: Concepts and Innovations. Ist ed., Springer. 3.Arvanitoyannis, 2013. Waste management for food industries. Food Science and Technology International series. 4.Prabhjot Kaur Sabharwal and Savitri Gupta, 2025. Handbook of Food waste and byproduct utilization. New Delhi Publishers. 		

Course Code	Course Title			Course Type
BP708T AEC6	Bio-similars, Vaccines and Macromolecule Sciences (Theory)			Elective
Credit	Hours Per Week (L-T-P)			Max. Hours
	L	T	P	
1	1	--	--	15
Maximum Marks	SE			ESE
50	20			30

COURSE OBJECTIVES:

The objectives of this course are to:

1. Introduce the fundamental concepts of biological macromolecules, biosimilars, and modern vaccine technologies used in pharmaceutical biotechnology.
2. Explain the physicochemical and functional characterization methods used for the analysis and comparability assessment of biologics and biosimilars.
3. Develop understanding of upstream and downstream manufacturing processes involved in the production of biopharmaceuticals and vaccines.
4. Describe quality control, stability testing, and immunogenicity assessment procedures applied to biologics and vaccine products.
5. Familiarize students with regulatory frameworks and approval pathways governing biosimilars and vaccines in India and global markets.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to
1	Describe the structure and therapeutic roles of biological macromolecules, biosimilars and vaccines.
2	Apply analytical methodologies for characterization and bioequivalence assessment.
3	Understand upstream and downstream processing and formulation protocols.
4	Understand quality control, stability testing, and immunogenicity assessment methods used for ensuring the safety and efficacy of biologics and vaccines.
5	Assess regulatory compliance requirements across the product lifecycle.

Detailed Syllabus

Unit No.	Topics	No. of Lectures
I	Introduction to Biosimilars, Vaccines and Macromolecules <ul style="list-style-type: none"> • Classes: Monoclonal antibodies (mAbs), cytokines, insulin, growth factors; primary/secondary/tertiary structures. • Biosimilars: Definition, rationale, types (e.g., erythropoietin, filgrastim). • Vaccines: Generations (live, subunit, viral vector, mRNA); adjuvants and 	3 hours

	<p>delivery systems.</p> <ul style="list-style-type: none"> • Industry landscape: Blockbuster biologics (Humira, Keytruda), Indian biosimilar market. 	
II	<p>Characterization Methodologies</p> <ul style="list-style-type: none"> • Physicochemical: SDS-PAGE, SEC-HPLC, peptide mapping, mass spectrometry. • Glycosylation analysis: N-linked glycans (HILIC, lectin arrays). • Functional assays: Cell-based potency, binding ELISA, ADCC. • Comparability for biosimilars: Fingerprinting (ICH Q5E). 	3 hours
III	<p>Manufacturing Protocols</p> <ul style="list-style-type: none"> • Upstream: Cell line development (CHO, HEK), bioreactors, media optimization. • Downstream: Harvesting, chromatography (affinity, ion-exchange), viral clearance. • Fill-finish: Lyophilization, aseptic processing, cold chain. • Process analytical technology (PAT) in biologics. 	3 hours
IV	<p>Quality Control and Stability Protocols</p> <ul style="list-style-type: none"> • Release testing: Host cell proteins (HCP), DNA, sterility, endotoxin (LAL). • Stability: ICH Q5C for biologics; subvisible particles, aggregation. • Immunogenicity assessment: ADA assays, neutralizing antibodies. • Vaccine QC: Potency, identity, safety (animal models). 	3 hours
V	<p>Regulatory Compliances and Case Studies</p> <ul style="list-style-type: none"> • Global: USFDA 351(k) biosimilar pathway, EMA guidelines, WHO prequalification. • India: CDSCO Biosimilar Guidelines 2021, DCGI vaccine approvals. • Documentation: BLA/CMC modules, PK/PD comparability studies. • Case studies: COVID-19 mRNA vaccines (Pfizer), Indian trastuzumab biosimilars. 	3 hours
<p>Recommended References (Preferably latest edition):</p> <ol style="list-style-type: none"> 1. Genomic and Precision Medicine by Geoffrey S. Ginsburg & Huntington F. Willard 2. Genomics and Personalized Medicine by Michael Snyder 3. Deep Medicine by Eric Topol 		

Course Code	Course Title			Course Type
BP708T AEC7	Precision Medicine (Theory)			Elective
Credit	Hours Per Week (L-T-P)			Max. Hours
	L	T	P	
1	1	--	--	15
Maximum Marks	SE			ESE
50	20			30

COURSE OBJECTIVES:

The objectives of this course are to:

1. Introduce the fundamental concepts, scope, and evolution of precision medicine and its relevance to modern pharmacy practice.
2. Provide an understanding of pharmacogenomics and the role of genetic variability in drug response, safety, and efficacy.
3. Explain the importance of biomarkers, targeted therapies, and companion diagnostics in personalized treatment strategies.
4. Introduce the emerging technologies such as artificial intelligence, big data analytics, and electronic health records in precision medicine.
5. Develop awareness of regulatory frameworks, ethical considerations, and clinical implementation challenges associated with genomic-based therapies.

COURSE OUTCOMES (CO):

CO No.	Upon successful completion of this course, the students will be able to
1	Define precision medicine and explain its evolution from conventional therapy to personalized healthcare approaches, highlighting the role of pharmacists and interdisciplinary collaboration.
2	Describe basic human genetics and pharmacogenomic principles, and interpret genotype–phenotype relationships affecting drug response and adverse drug reactions.
3	Analyze the role of genetic polymorphisms (e.g., CYP450 enzymes) and utilize pharmacogenomic resources and databases such as PharmGKB and CPIC in clinical decision-making.
4	Classify biomarkers and evaluate their role in targeted therapies and companion diagnostics, with reference to real-world clinical case studies as targeted nanocarriers, antibody–drug conjugates, and smart delivery systems
5	Define precision medicine and explain its evolution from conventional therapy to personalized healthcare approaches, highlighting the role of pharmacists and interdisciplinary collaboration.

Detailed Syllabus

Unit No.	Topics	No. of Lectures
I	Introduction to Precision Medicine and Its Relevance to Pharmacy Definition and scope of precision medicine Evolution from “one-size-fits-all” to personalized approaches Key components: genomics, epigenetics, environmental factors, lifestyle Role of pharmacists in precision medicine Interdisciplinary nature (clinicians, bioinformaticians, pharmacologists)	3 hours
II	Pharmacogenomics in Drug Response and Safety Basic human genetics relevant to pharmacy Genotype-phenotype relationships Genetic polymorphisms: CYP450 enzymes (CYP2D6, CYP2C9, etc.) FDA drug labelling and pharmacogenomic biomarkers Tools/databases: AlphaGenome, PharmGKB, CPIC, SNPedia	3 hours
III	Biomarkers, Targeted Therapy, and Companion Diagnostics Types of biomarkers: predictive, prognostic, diagnostic Role of biomarkers in targeted therapy Companion diagnostics: regulatory approval and clinical application Case study: Trastuzumab and HER2 testing in breast cancer Lab-on-chip and biosensor technologies Targeted nano-delivery in oncology Antibody-drug conjugates (ADCs) Smart delivery systems (stimuli-responsive biosensors)	4 hours
IV	Technology, AI, and Big Data in Precision Medicine Role of AI, machine learning, and data analytics in precision medicine Electronic Health Records (EHRs), clinical decision support systems Integration of genomic data with patient profiles Examples of AI-driven drug discovery Data security and interoperability	2 hours
V	Regulatory, Ethical, and Clinical Implementation Regulatory guidelines (US FDA, EMA, CDSCO) for genomic-based therapies Clinical trial design for precision drugs Cost-effectiveness and access in low-resource settings Ethical issues: genetic testing, informed consent, data ownership Future of pharmacy practice in the precision medicine era	3 hours
Recommended References (Preferably latest edition): <ol style="list-style-type: none"> <u>Genomic and Precision Medicine</u> (3rd Edition) by Geoffrey S. Ginsburg & Huntington F. Willard <u>Genomics and Personalized Medicine</u> by Michael Snyder <u>Deep Medicine</u> by Eric Topol 		